搜索
Agenus Inc
AGEN添加自选
3.490USD
+0.080+2.35%
收盘 07/02, 13:00（美东）报价延迟15分钟
134.44M总市值
1.69市盈率 TTM
关键数据
3.400今开
3.515最高
680.58K成交量
1.69市盈率 TTM
亏损市盈率动
--股息TTM
1.77%换手率
3.410昨收
3.370最低
1.71M成交额
亏损市盈率静
-0.61市净率
0.00%股息率 TTM
32.32%ROA
7.34052周最高
0.72量比
-227.43M净利润
38.52M总股本
2.0638每股收益TTM
1.58Beta
-556.54%ROE
2.71052周最低
4.25%振幅
100.00%毛利率
134.44M总市值
0.09回报/风险
5.00%风险率
TradingKey Agenus Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
Agenus Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名125/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价15.50。中期看，股价处于下降通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Agenus Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Agenus Inc亮点
亮点风险
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
估值高估
公司最新PE估值1.69，处于3年历史高位
机构减仓
最新机构持股10.91M股，环比减少8.15%
分析师目标
根据
2
位分析师
买入
评级
15.500
目标均价
+354.55%
涨幅空间
Agenus Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Agenus Inc简介
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
公司代码AGEN
公司Agenus Inc
CEOArmen (Garo H)
网址https://agenusbio.com/
相关品种
热门品种
常见问题
Agenus Inc(AGEN)的当前股价是多少？
Agenus Inc(AGEN)的当前股价是 3.49。
Agenus Inc的股票代码是什么？
Agenus Inc的股票代码是AGEN。
Agenus Inc股票的52周最高点是多少？
Agenus Inc股票的52周最高点是7.34。
Agenus Inc股票的52周最低点是多少？
Agenus Inc股票的52周最低点是2.71。
Agenus Inc的市值是多少？
Agenus Inc的市值是134.44M。
现在Agenus Inc(AGEN)的股票是买入、持有还是卖出？
根据分析师评级，Agenus Inc(AGEN)的总体评级为买入，目标价格为15.50。
Agenus Inc(AGEN)股票的每股收益（EPS TTM）是多少
Agenus Inc(AGEN)股票的每股收益（EPS TTM）是-0.00。